Nice Recovery in U.S. and Emerging Markets Stocks

U.S. markets have rebounded nicely. The S&P 500 has made up most of its late-December-through-mid-February correction, and by all appearances it’s ready to start chewing through the November–December area of overhead resistance. The Nasdaq, while also steaming higher, isn’t as far along as the S&P. All in all, it’s a good situation, helped by good employment numbers in the U.S. and reassurances from the Fed that interest-rate increases will be sparing through the rest of the year.

Both the iShares MSCI Emerging Markets ETF (EEM) and the Golden Dragon China ETF (PGJ) have experienced a quick pullback and a nice recovery. EEM is still a bit stronger than PGJ, but both ETFs are doing well and have climbed atop their 200-day moving averages. Our intermediate-term Emerging Markets Timer remains bullish, and having EEM and PGJ both surmounting their 200-day moving average is a good sign for the longer-term trend. Momentum is an important part of our strategy, and an uptrend with longevity is stronger than one without.

The major indexes were all up during the morning session, but dipped in the afternoon to close narrowly mixed. The Dow fell 32 points (0.18%), the S&P 500 lost 4 points (0.20%), and the Nasdaq rose a scant one point (0.01%). The iShares MSCI Emerging Markets ETF (EEM) was flat, down 0.03 cents (0.09%) to finish at 34.25.

This is an excerpt from Cabot Emerging Markets Investor, which seeks to capitalize on the enormous potential in emerging market countries. Chief Analyst Paul Goodwin has been a researcher and writer for over 30 years and a member of the Cabot investment team since 2005.

Subscriber comments on Cabot Emerging Markets Investor

Paul Goodwin can be found on Google Plus.

Stock Picks


This stock could rise 50% before becoming fairly valued.

This hot technology company is growing like a weed, thanks to products that speed up cloud communications.

This stock is somewhat well known, but far from well loved.

Cabot Wealth Advisory

How to Find Great Growth Stocks in a Scary Market

By Paul Goodwin on October 21, 2016

Even in today’s scary market, there are great growth stocks out there. Here’s how to find them—and how to avoid the kind of losses that can haunt your portfolio.Read More >

Buy This Small-Cap Tech Stock as the Nasdaq Thrives

By Tyler Laundon on October 20, 2016

Technology stocks are thriving, as the Nasdaq has been outpacing the S&P 500 and the Dow for months. And one small-cap tech stock in particular is outperforming the industry’s big boys. Read More >

Is Allergan (AGN) Still an Undervalued Stock?

By Crista Huff on October 18, 2016

Five months ago, Allergan (AGN) was an undervalued stock with tons of growth potential. It's up 21% since then, but still has plenty of upside. Here's why.Read More >